T cell immunotherapies teach a patient’s immune system to recognise and kill cancer cells. These treatments have worked well for some cancer types but not for others. One reason is that scientists did not fully understand how the T cell receptor (TCR) starts the activation signal.
Researchers used cryo-EM to image the TCR in a biochemical environment that copied its membrane. They put the multi-protein receptor into nanodiscs and used a lipid mix like the natural membrane. In this setup the receptor was closed at rest and opened when it met an antigen-presenting molecule. This finding may help scientists make the therapies work for more patients.
Difficult words
- immunotherapy — treatment that uses a person's immune systemimmunotherapies
- receptor — protein on a cell that receives signals
- activation — start of a process or response in cells
- cryo-EM — a method to image molecules at very low temperature
- nanodisc — small lipid disc used to hold proteinsnanodiscs
- antigen-presenting — molecule that shows foreign parts to immune cells
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Do you think this research could help more patients? Why or why not?
- What would you ask scientists about how the receptor opens?
- Have you heard of cryo-EM before? What do you think it does?
Related articles
Egyptian university and pharma join to create Africa’s first biotechnology academy
The American University in Cairo and Minapharm have formed a partnership to set up what the university calls the first African academy for biotechnology. The initiative starts early this year to strengthen education, research and industry links.
Personalized DNA vaccine shows promise against glioblastoma
A phase 1 trial found the personalized DNA vaccine GNOS-PV01 is safe and shows early signs of activity against glioblastoma. The small study at Siteman Cancer Center and WashU Medicine reported immune responses and encouraging clinical outcomes.
Engineered bacteria produce tagatose sweetener
Tufts researchers engineered Escherichia coli to make tagatose, a rare sugar that can substitute for table sugar. They used a slime mold enzyme and another enzyme to convert glucose, producing higher yields; tagatose is low‑calorie and FDA‑recognized as safe.